Professor Benjamin Kile
Executive Director and CEO of the Garvan Institute of Medical Research, Professor Benjamin Kile is an internationally recognised medical researcher who has made contributions to the understanding of cancer, stem cells and inflammatory disease. His work has shed light on the mechanisms of programmed cell death, informing the development of the BH3 mimetics, a new class of cancer drugs approved by the FDA in 2016. Professor Kile has a distinguished research leadership background, having occupied senior roles at the Walter and Eliza Hall Institute, Monash University, and the University of Adelaide. He made foundational contributions to the establishment of the National Drug Discovery Centre, the South Australian immunoGENomics Cancer Institute, and the Bragg Comprehensive Cancer Centre.
Medical Minds Podcast
Awards
- 2016
Fellow - Australian Academy of Health and Medical Sciences
- 2015
Merck Millipore Research Medal - Australian Society for Biochemistry & Molecular Biology
- 2013
Committee for Melbourne Future Focus Group Jack Smorgon Alumni Award
- 2013
Gottschalk Medal of the Australian Academy of Science
- 2011
National Health and Medical Research Council 10 of the Best Research Projects 2011
- 2010
Australian Federal Government Science Minister's Prize for Life Scientist of the Year
- 2008
Burnet Prize of the Walter and Eliza Hall Institute
- 2007
Australian Institute of Policy and Science Young Tall Poppy Award
- 2006
Charles Perkins Centre Award for Outstanding Contributions to Cardiovascular Research
- 2005
International Society on Thrombosis and Haemostasis Young Investigator Award
- 2005
International Society on Thrombosis and Haemostasis Young Investigator Award
- 1997
Dean's Honour List - Faculty of Science - University of Melbourne